Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Indian pharmaceutical firm Dr Reddy's Laboratories has teamed up with the UK's Argenta Discovery to jointly develop a novel approach to the treatment of chronic obstructive pulmonary disease.
Subscribe to our email newsletter
The two companies will collaborate to identify clinical candidates from a certain class of Dr Reddy’s’ compounds for use as potential treatments for chronic obstructive pulmonary disease (COPD). Both the parties will jointly develop the selected candidates from the preclinical stage up to phase IIa, the proof-of-concept level.
On successful completion of a phase IIa trial, the companies may either license-out the candidate for further development and commercialization to a larger pharmaceutical company or continue the further co-development and commercialization themselves.
Both Dr Reddy’s and Argenta have agreed to fund the joint collaboration up to proof-of-concept. The financial terms of the agreement have not been disclosed.
“We are delighted to be working with Dr Reddy’s, which is establishing a growing reputation within the global pharmaceutical industry. We are proud that Argenta’s expertise and experience in drug development and respiratory disease has been recognized by Dr Reddy’s and we look forward to a long and fruitful collaboration,” said Dr Chris Ashton, CEO of Argenta Discovery.